Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Enterprise Value: 2013-2025

Historic Enterprise Value for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to $1.7 billion.

  • Ocular Therapeutix's Enterprise Value rose 81.77% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $556.3 million, marking a year-over-year increase of 365.69%. This contributed to the annual value of $950.5 million for FY2024, which is 500.65% up from last year.
  • As of Q3 2025, Ocular Therapeutix's Enterprise Value stood at $1.7 billion, which was up 55.38% from $1.1 billion recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Enterprise Value high stood at $1.7 billion for Q3 2025, and its period low was $138.7 million during Q3 2023.
  • Over the past 3 years, Ocular Therapeutix's median Enterprise Value value was $816.0 million (recorded in 2025), while the average stood at $718.3 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 80.44% in 2022, then skyrocketed by 569.92% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Enterprise Value (Quarterly) stood at $369.8 million in 2021, then dropped by 10.71% to $330.2 million in 2022, then slumped by 52.07% to $158.3 million in 2023, then surged by 500.65% to $950.5 million in 2024, then spiked by 81.77% to $1.7 billion in 2025.
  • Its Enterprise Value was $1.7 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $816.0 million in Q1 2025.